Indications |
Oral Hypertension in phaeochromocytoma Adult: As hydrochloride: Initially, 10 mg once or bid. Gradually increase, as necessary, to 1-2 mg/kg daily in 2 divided doses. Child: Initially, 0.2 mg/kg (max: 10 mg) once daily. Increase by 0.2 mg/kg increments. Maintenance dose: 0.4-1.2 mg/kg/day every 6-8 hr; higher doses may be required. Oral Urinary retention Adult: As hydrochloride: 10 mg bid. Intravenous Operative cover in patients with phaeochromocytoma Adult: As hydrochloride: 1 mg/kg daily in 200 ml sodium chloride 0.9% infused over at least 2 hr. Intravenous Severe shock Adult: As hydrochloride: 1 mg/kg daily in 200-500 ml sodium chloride 0.9% infused over at least 2 hr. |
Contraindications |
Conditions in which fall in BP would be dangerous. |
Warnings / Precautions |
Heart failure, ischaemic heart disease, cerebrovascular disease, renal impairment. Porphyria. Pregnancy and lactation. Discontinue use if angina develops or worsens. Respiratory tract infections. Elderly. |
Adverse Reactions |
Nasal congestion, slight GI irritation, miosis, postural hypotension with dizziness, fatigue, compensatory tachycardia, inhibition of ejaculation, dry mouth, decreased sweating, confusion, drowsiness, convulsions (rapid IV infusion). |
Overdose Reactions |
Symptoms: Hypotension, tachycardia, lethargy, dizziness, shock. Management: Treat hypotension and shock by postural measures and parenteral fluid volume replacement. Do not use epinephrine. |
Drug Interactions |
May antagonise the effects of α-adrenergic stimulating agents. Increased toxicity with β-blockers. Alcohol ingestion may exaggerate hypotensive effects. Potentially Fatal: Cardiac-accelerating and hypotensive effects may be enhanced by epinephrine and other drugs that stimulate both α- and β-adrenergic receptors. Additive hypotensive effects with sildenafil, tadalafil, vardenafil. See Below for More phenoxybenzamine Drug Interactions |
Mechanism of Actions |
Phenoxybenzamine produces an irreversible (non-competitive) blockade by binding covalently to α-receptors in the smooth muscle. Onset: Gradual over several hr (oral). Duration: 3-4 days (oral/IV). Absorption: Incompletely and variably absorbed from the GI tract (oral). Metabolism: Hepatic. Excretion: Via urine and bile. Plasma half-life: 24 hr (IV). |
Storage Conditions |
Oral: Store at 25°C (77°F). |
ATC Classification |
C04AX02 - phenoxybenzamine ; Belongs to the class of other peripheral vasodilators. |
Storage |
Oral: Store at 25°C (77°F). |
Available As |
|
Phenoxybenzamine
Post Review about Phenoxybenzamine Click here to cancel reply.
Phenoxybenzamine Containing Brands
Phenoxybenzamine is used in following diseases
Drug - Drug Interactions of Phenoxybenzamine
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.